Showing posts with label proteomics. Show all posts
Showing posts with label proteomics. Show all posts

Friday, November 13, 2026

An atlas of all the plasma proteins that pass the blood-brain barrier of the mouse

Good news! Amazing stuff!

It is very surprising to read in the abstract of this paper that in the year 2026 "the scale and function of physiological blood-to-brain protein transport remain largely unknown". Hard to believe!

"... Now, scientists have created an atlas of all the proteins that make the guest list for mouse brains—including one crucial to limiting Alzheimer’s onset.

Researchers used protein-labeling chemistry to tag 861 proteins in mouse blood. Of those, only 92 could pass through the blood-brain barrier. The selection included proteins produced throughout the body, especially in the liver.
Once inside the brain, the different proteins were sent to different kinds of brain cells, where they served specific roles such as maintaining connections between neurons. ..."

"... Multiple organs in the body, such as the liver and kidney, release different proteins into the blood at different times. This means the specific mix of protein types in blood plasma—the liquid portion of the blood—can relay important information to the brain about the current state of the body. But with the blood-brain barrier, which of these proteins can the brain sense? ...

Of the 861 proteins the scientists tracked, the blood-brain barrier only allowed 92 to enter the brain. Most of these proteins were produced in distant parts of the body, especially the liver. The findings suggest that the blood-brain barrier acts as a gatekeeper, using specialized receptors to identify and transport specific plasma proteins from the body into the brain. ...

The team also found that, once inside the brain, different proteins are directed to specific types of brain cells, where they carry out specialized functions. ...

For example, a protein made in the liver travels to the brain to support cells known as astrocytes. Once in the brain, the protein—known as apolipoprotein A1, or APOA1—activates a pathway that maintains healthy connections between neurons. Failure of this pathway has previously been linked to a higher risk of Alzheimer’s disease ..."

From the highlights and abstract:
"Highlights
• Bioorthogonal chemistry and proteomics map the blood-brain barrier transportome
• Each permeable protein homes to distinct brain cell types to support cell functions
• Blood-brain barrier transport dysfunction arises early in Alzheimer’s disease models
• Liver-derived APOA1 engages astrocyte ABCA1 to rescue Alzheimer’s dysfunction in mice

Summary
The blood-brain barrier (BBB) has been defined primarily by what it excludes, yet the scale and function of physiological blood-to-brain protein transport remain largely unknown.
Using bioorthogonal proteomics, we find that the healthy BBB samples 191 plasma proteins and permits 92 into the brain parenchyma. Enriched for carrier and metabolic functions, these proteins home to distinct brain cell types, such as apolipoprotein A1 (APOA1) to astrocytes and alpha-1 antitrypsin (SERPINA1) to microglia.
This cell-type tropism relies on a BBB-parenchyma receptor hand-off: APOA1 crosses the BBB via SR-B1 and engages astrocytic ATP-binding cassette transporter A1 (ABCA1), a key Alzheimer’s risk gene, driving cholesterol efflux that supports synapse integrity. Unlike LPS-induced nonspecific leakage, early-stage 5xFAD mice show selective BBB transport remodeling, with reduced APOA1 and increased SERPINA1 uptake.
Hepatic APOA1 overexpression restores APOA1 in the 5xFAD brain, rescuing astrocytic, synaptic, and behavioral deficits.
These findings recast the BBB as a selective interface that recruits neuroprotective circulatory proteins for brain health."

ScienceAdviser

Study Rewrites the Rules of the Blood-Brain Barrier (original news release) "Gladstone scientists discover the dynamic barrier—long defined by what it excludes—imports an unexpected degree of protective proteins into the brain, revealing a new blueprint for treating Alzheimer’s disease."


Graphical abstract


Figure 1 A bioorthogonal proteomics strategy to detect plasma proteins within the healthy brain


Friday, October 30, 2026

A unifying mechanism for cancer-driving mutations

Amazing stuff! Cancer is history (soon)!

"A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators. The findings suggest new therapeutic strategies for a variety of cancer types.

The study ... focused on a protein complex called the BAF complex, which regulates gene activity in the nucleus. Mutations in genes that encode subunits of this complex are found in tumors as different as lymphoma, breast cancer, ovarian cancer and liver cancer, but the common mechanism underlying this broad connection to cancers has been elusive.
In the study, the scientists showed that these BAF mutations effectively allow the three-dimensional architecture of DNA to be reshaped extensively by a protein called CTCF. This shifts gene activity in a direction that promotes malignancy, but deleting CTCF in an animal model reverses the effect. ...

When the BAF complex is lost, CTCF binding increases at thousands of sites across the genome and leads to a widespread reshaping of the three-dimensional loops and folds of DNA. These changes disrupt the normal contacts between genes and elements that regulate them and alter gene activity in a way that leads to faster cell division. ...

In mouse models and human patient data, the team found confirmatory evidence of CTCF’s role in BAF-mutant cancers, including evidence that disruptions of CTCF are associated with better patient outcomes. ..."

From the abstract:
"The BAF (also known as mammalian SWI/SNF) chromatin remodelling complexes are essential regulators of nucleosome positioning and transcription factor binding.
Loss-of-function (LOF) mutations in genes encoding components of the BAF complexes are among the most frequent across cancer types.
However, a unifying mechanism that explains their widespread disruption remains unclear.
Here we disrupted BAF function through pharmacological inhibition and ARID1A deletion across various mammalian cell types and tissues and observed a conserved chromatin response: increased accessibility at CTCF-binding sites. ARID1A LOF alone was sufficient to drive these changes, which demonstrates that canonical BAF (cBAF) disruption is the key driver of CTCF gain.
Genomic profiling showed increased CTCF and SMC3 occupancy, which reveals an antagonistic relationship between cBAF and CTCF–cohesin complexes. Furthermore, cBAF loss restructured 3D genome organization, which led to a strengthening of topologically associating domain boundaries and subdivision of large domains into smaller insulated structures. Long-range enhancer–promoter loops were replaced by shorter, promoter-proximal loops anchored at CTCF-enriched sites. To determine how CTCF function is enabled following cBAF loss, we profiled CTCF-interacting cofactors and found that CTCF binds directly to fully assembled PBAF. After cBAF depletion, PBAF was recruited to sites of increased CTCF occupancy, which demonstrates that there is an antagonistic switch between SWI/SNF subcomplexes.
In vivo, conditional Arid1a deletion in primary mouse cells resulted in the expansion of a highly proliferative population marked by elevated accessibility at CTCF sites.
This phenotype was fully reversed by either Ctcf or Pbrm1 deletion, which establishes that cBAF and the activity of CTCF and PBAF have contrasting roles."

A unifying mechanism for cancer-driving mutations | Cornell Chronicle



Fig. 1: BAF LOF preferentially opens chromatin at CTCF sites across diverse cell types.


Wednesday, October 21, 2026

AlphaFold researchers tackle molecules atom by atom and competitor Nvidia is close behind

Good news! The race is on!

"... Researchers expanded on a previous model largely built on amino acids, RFdiffusion2, by training it on a large swath of protein structures including backbones, side chains, and nucleic acids. The team even got as specific as the location of individual atoms or hydrogen bonds. The resulting model, RFD3, could design protein functional sites, RNA molecules, and enzymes from scratch, outperforming other models used to make protein components. In laboratory experiments, RFD3 designed two enzymes, one that broke down a toxic molecule and one that split another protein in two. ..."

From the abstract:
"The catalytic and other sophisticated functions of biomolecules arise from the placement of many atoms in three-dimensional space.
Here, we describe a generative artificial intelligence method for biopolymers, RFdiffusion3 (RFD3), which employs free atom diffusion to satisfy complex sets of atomic constraints more rapidly and accurately than previous methods across several challenges from enzyme design to RNA structure design.
We demonstrate experimentally the power of the RFD3 pipeline for enzyme design by designing de novo phosphotriesterases with a complex active site architecture incorporating a carbamylated lysine coordinating two metal ions and zinc proteases specific for the transthyretin protein involved in amyloid diseases; in both cases we obtain active catalysts in zero shot 96 construct design campaigns."

"Researchers at the UW Medicine Institute for Protein Design today [10/21/2026] introduced RFD4-Proteina, an open, generative model co-developed by IPD and NVIDIA Corp. The model uses biomolecular reasoning to improve how well scientists can design new proteins with specific functions. ..."

ScienceAdviser



Researchers [of the University of Washingto] achieve major advance in protein design (using Nvidia) "A new open-source generative model surpasses its predecessors by using biomolecular reasoning to solve difficult design problems."



Fig. 1 All-atom protein design with RFdiffusion3.
a, Depiction of 100 step RFD3 diffusion trajectory, predicting both backbone and sidechain atoms. (top) noisy coordinates at different timesteps. (bottom) the network prediction at each time-step.
b, Generation of biomolecular interactions. (top) different conditions can be fed to the model. (bottom) sample output structures for each input condition.
c, Model architecture. Arrows show information flow, grey boxes indicate modules with learnable parameters. d, Inference times for RFdiffusion variants across length scales. RFD3 is an order of magnitude faster than previous versions of RFdiffusion because of its simplified architecture (runtimes are measured on NVIDIA A6000 GPUs).


Monday, October 19, 2026

Designed Enzymes Precisely Cut Targeted Proteins in Lab Tests

Good news!

"... The researchers specified a target sequence, designed enzymes to cut those targets, and verified their accuracy in doing so across a range of experimental settings. They tested the new enzymes on purified proteins, sequences drawn from proteins implicated in Alzheimer’s disease and amyotrophic lateral sclerosis, and, in one study, inside living human cells cultured in the lab. ...

The functional properties of proteases also enable therapeutic approaches ... These could include destroying a viral protein or a bacterial toxin outright, clearing a misfolded protein that accumulates in neurodegenerative disease, or snipping a protective cap off a drug so it functions only in the tissue where it is needed. ..."

From the abstract (1):
"Despite advances in de novo enzyme design, success has been largely limited to low-energy-barrier model reactions.
Amide bonds such as those linking amino acids along the peptide backbone are stable for hundreds of years in neutral aqueous solution because of the high energy barrier to hydrolysis.
Here we describe the de novo design of enzymes that use an activated cysteine nucleophile to hydrolyse the polypeptide backbone in a sequence-dependent manner, with a success rate of 13/69 = 19% and rate enhancements over the background reaction (kcat/kuncat) of up to 3 × 107.
The designed proteases have folds that are very different from proteases in nature (TM score < 0.50), and six crystal structures are very close to the design models (Cα root mean squared deviation of <1.2 Å), highlighting the capacity for generalization and the accuracy of the design methodology.
Experimental and computational analyses suggest that the remaining gap in activity to the most active native cysteine proteases arises from imperfections in active-site preorganization and substrate positioning.
The designed proteases efficiently cleave their targets in mammalian cells, opening the door to a wide range of synthetic biology applications."

From the abstract (2):
"De novo design of enzymes that cleave amide bonds represents a major challenge.
Here we use RFdiffusion methods to de novo design proteins with water-activating zinc-based active sites adjacent to a peptide substrate binding pocket.
Of 135 designs tested, 36% catalyse cleavage of their cognate peptide substrates at the targeted scissile bond.
The best design accelerates peptide-bond hydrolysis by more than 108-fold relative to the uncatalysed reaction; four substitutions increase this acceleration to more than 1010-fold by improving active-site preorganization.
We use this approach to design metalloproteases that selectively cleave the human disease-associated proteins TDP-43, amyloid-β and serum amyloid A, with rate enhancements of up to 109-fold.
We further design caged cytokines and receptor antagonists that are selectively activated by the designed proteases, enabling bioorthogonal control of cell state. Thus, de novo design can yield highly active, programmable proteases with applications in therapeutics, biotechnology and bioremediation."

Designed Enzymes Precisely Cut Targeted Proteins in Lab Tests - Human Progress

Molecular ‘scissors’ open path to new therapies "In two studies published in Nature, computationally designed enzymes cut disease-related proteins at precise sites."



De novo design of cysteine proteases (1, preprint, open access)


Computational design of metalloproteases (2, preprint, open access)


Fig. 1 Computational design and experimental testing approach. (1)


Wednesday, September 16, 2026

Virtual cell model predicts best cancer drug

Good news! Cancer is history (soon)!

Again Nature journal uses the horrible ideological term "people" instead of women!!!

triple-negative breast cancer (TNBC)

"A new ‘virtual cell model’ could help to choose more personalized treatments for women people with hard-to-treat triple-negative breast cancer. Researchers trained the prototype artificial-intelligence-based model, called ProteinTalks, on millions of protein measurements collected over time from breast cancer cell lines that were treated with dozens of antitumour drugs. The model did a good job of predicting how cells would respond to drugs it hadn’t seen before and also real-world clinical outcomes. “This is the first time that a virtual cell model goes out of the laboratory and is tested in a clinical scenario,” ...

In experiments using biopsies taken from individuals with TNBC, the virtual cell model showed promising results in identifying the same drugs that would prove to be effective when given to women people. The authors say this raises the possibility of more personalized care for TNBC, which accounts for 15–20% of breast cancer cases. ...

In their study, Guo and his colleagues aimed to develop a virtual cell model of breast cancer cells using proteomics data. They trained an AI model on more than 38 million protein measurements collected from 18 breast cancer cell lines, 16 of which were TNBC cells. The researchers treated the cells with 63 antitumour drugs that have been approved by the US Food and Drug Administration, and 59 drug combinations. ..."

From the abstract:
"Artificial intelligence-empowered virtual cell models represent an emerging approach for in silico drug discovery, yet most existing approaches lack large-scale, time-resolved perturbation proteomics data and interpretable frameworks for predicting therapeutic responses.
Here we generated more than 38 million temporal protein-abundance measurements from systematically perturbed breast cancer cell lines, and developed ProteinTalks, a virtual cell model.
Central to ProteinTalks is the synergy of this large-scale dynamic proteomic resource and the model architecture, enabling a new pretraining framework that learns transferable dynamical latent representations from temporal proteome trajectories. By modelling how proteins respond conditionally to different perturbations, this approach enables the model to function as an operational tool for diverse drug discovery tasks: predicting drug efficacy and synergy, discovering new drug combinations, probing proteins associated with drug resistance, stratifying patient responses and prioritizing drug candidates for patient organoids.
It also shows robust transferability, extending beyond cell lines to patient-derived organoids and clinical biopsies, generally achieving higher performance than the selected benchmark implementations under the evaluated protocols.
Together, ProteinTalks shows how scalable pretraining of transferable dynamic representations enables operational, dynamics-aware, proteomics-based virtual cell models to advance in silico drug discovery."

Nature Briefing: Translational Research

AI model predicts which breast-cancer drugs work best (behind paywall) "Model trained on millions of protein measurements can gauge drug effectiveness in tissue samples taken from people with triple-negative breast cancer."

An operational perturbation proteomics-based virtual cell model (no public access, but article above contains link to PDF)



Fig. 1 Overview of this perturbation proteomics study.


Fig. 3 Development and performance of the ProteinTalks model.


Friday, July 10, 2026

Evolution of a core ribosomal innovation in octopus leading to less error prone proteins

Amazing stuff!

"Octopuses are among the strangest creatures on Earth—right down to their molecules. New research has found that octopuses of a certain lineage have a mutation not seen in any other organism that makes their cellular machinery extremely accurate at creating proteins. As a result, their proteins are less likely to form toxic clumps. ...

The team serendipitously discovered a change in the octopus gene encoding ribosomal RNA (rRNA), which is part of the cellular machinery that translates mRNA messages into proteins. This region of the rRNA sequence is identical in every other known organism, from humans to bacteria. But in octopuses, the mutation causes the rRNA to break into two fragments and occurs right at a crucial spot where the rRNA matches the right amino acid to the right genetic instruction. Ribosomes with this break made about 50% fewer errors than other species’ ribosomes when incorporating amino acids into a protein. ..."

From the abstract:
"Much of biology focuses on how genetic changes mediate new functions, but less attention is given to adaptations in other steps of the central dogma.
Octopuses exhibit complex nervous systems and sophisticated behaviors that rival vertebrates, but via an entirely divergent evolutionary history.
Here, we serendipitously discovered that octopus ribosomes contain a structural break in the core ribosomal RNA that is unique among all animals.
This break site enhances translation fidelity to reduce miscoding and subsequent protein aggregation, even when engineered into evolutionarily distant bacterial ribosomes.
Furthermore, high fidelity translation by octopus ribosomes supports proteomic stability during extensive RNA editing observed in cephalopods, suggesting synergy between distinct non-canonical modes of gene regulation.
This adaptation emerged in recently derived octopuses with expanded nervous systems, thereby revealing a mechanism that could broadly support the evolution of novel organismal traits."

ScienceAdviser


Adaptive Innovation in the Octopus Ribosome (PhD dissertation by one of the involved researchers, 2025)



Figure 1. The octopus has a unique structural adaptation in the conserved ribosomal core


Sunday, May 17, 2026

New, potent peptides discovered in carpenter ant venom with antimicrobial and antifungal activity

Good news!

"At first, it was thought the sting of all hymenopterans—from bees to ants—came predominantly from formic acid, which was first identified in the venom of wood ants back in 1670. Since then, toxinologists have come to appreciate the diversity of toxins in this insect order, especially when it comes to peptides, including honeybees’ inflammatory melittin to bullet ants’ excruciating poneratoxin. But until now, the idea has persisted that ants in the subfamily Formicinae, which includes carpenter ants, rely almost solely on formic acid.

When researchers compared the genomes of eight carpenter ant species, they spotted almost three dozen venom peptides—a veritable “arsenal” thus far unique to this subfamily of ants. Broadening their genetic search still wider, the team found these peptides—dubbed formicitoxins— in at least 20 other formicine genera.

These small proteins do all sorts of helpful things. “Some of the peptides demonstrate remarkable antifungal properties ,” ... which may explain why the ants spray their venom on their young. “While concentrated formic acid has strong immediate antimicrobial effects, the formicitoxins may serve as a persistent antifungal protective cloak after formic acid has lost its potency due to evaporation, dilution, or neutralization,” the team explained in the paper. Some formicitoxins were potent antimicrobials, which is especially intriguing given that carpenter ants are known to consume their own venom to modulate their gut microbiome ..."

"In addition to serving as biochemical weapons for offense and defense, the venoms produced by ants in the subfamily Formicinae also fulfill additional roles. For example, the ants use it to protect their nests from pathogens. It has long been assumed that the primary constituent of these venoms, formic acid, was responsible for these functions. ... a team of researchers ... has now shown that these venoms also contain a complex mixture of peptidic compounds and other bioactive substances. The discovery of these substances opens up new possibilities in the field of medical research. It also has the potential to shed new light on immune defenses and how social insect communities deal with microbes.  ..."

From the abstract:
"Venom peptides are key to the evolutionary success of most venomous animals, including stinging ants. The stingless ant subfamily Formicinae is thought to rely solely on formic acid in their venoms, despite early, unsubstantiated hints of proteinaceous venom constituents.
Here, we show that carpenter ants, the largest formicine genus, produce a diverse venom peptide arsenal. Mass spectrometry and transcriptomics across eight geographically distant species uncovered 35 peptides, formicitoxins, belonging to two gene families.
Several formicitoxins display antifungal activity. Application to pupae delays fungal outgrowth, suggesting a role of the peptides in colony hygiene. Genome analyses revealed that formicitoxins are widespread but variable across the Formicinae. Our findings overturn the paradigm of formicine venoms as simple acid sprays and establish them as a source of bioactive peptides."

ScienceAdviser

Ant Venom Serves Many Functions (original news release) "Groundbreaking discovery of antimicrobial peptides in ant venom has far-reaching implications"


Fig. 1 Fig. 1. Analysis of C. nicobarensis venom.
(A) C. nicobarensis major worker during acidopore grooming.
(B) Total ion current chromatogram of C. nicobarensis venom. Major peaks corresponding to venom peptides are labeled as formicitoxins FRTX1-Cnic1a (LDIKEIINKIISDIKEKIAKAL), FRTX2-Cnic1a (DIVSFLLELPKIIEEFFLKLINLFKLIF), and FRTX2-Cnic2a (NILSNIIDSIIHLLFEDFSRIFL). Signals corresponding to N-acylethanolamines (NAEs) are labeled as linoleoyl ethanolamide (LEA), oleoyl ethanolamide (OEA), linoleamidoethyl formate (LEA-f), and oleamidoethyl formate (OEA-f).
(C) Dissected venom apparatus of a C. nicobarensis major worker as used for extraction of venom and RNA.
(D) MALDI mass spectrum of C. nicobarensis venom showing molecular ions of FRTX2-Cnic1a and FRTX2-Cnic2a along with potassium adducts (+39 Da) and formyl esters (+28 Da). Inset: Magnified mass/charge ratio (m/z) range 3350 to 3550.
(E) Structures of LEA, OEA, LEA-f, and OEA-f.


Thursday, May 07, 2026

Revolving Doors and Efficient Engines: How Proteins Escape a Molecular Tangle and misfolded proteins

Amazing stuff!

"... Machines from the AAA+ family, which exist in the cells of all living organisms from bacteria to humans, can, among their many functions, recognize misfolded protein chains and swiftly unravel them.

Researchers ... have deciphered this sophisticated mechanism, which is both fast and remarkably efficient. Their findings ... reveal how cells perform quality control on their proteins, and may help explain why this control fails in diseases such as neurodegeneration and cancer. They may also provide inspiration for the development of highly efficient artificial molecular machines. ...

When a protein chain in the cell becomes entangled or misfolded, these machines come to the rescue, unraveling the chain by threading it through the channel. ...

Until now, it was unclear how a tiny molecular machine converts chemical energy within the cell into an effective mechanical pulling action. ...

To address this question, the researchers ... developed a method that allowed them to monitor, in real time rather than through frozen snapshots, the passage of a protein chain through the molecular machine. They used fluorescent sensors attached to the milk protein casein and to the AAA+ machine that processes it. A green sensor was attached to the casein, an orange sensor to the machine’s entrance and a red sensor to its exit. ...

“Loops in the channel wall protrude into its interior and, like the wings of a revolving door, determine the preferred direction of movement. The machine uses energy to ensure that these loops oscillate in the correct direction.” ...

In the final stage of the study, the researchers focused on failure events, in which threading through the channel was not completed. “These events lasted a relatively long time,” ... “We found that in their course, the protein moved back and forth within the channel until it mistakenly exited from the same end where it had entered. This indicates that there are no large energy fluctuations or powerful forces inside the channel, but rather a subtle motion-guiding mechanism that is occasionally prone to error.” ..."

From the abstract:
"How biological machines harness ATP to drive mechanical work remains a crucial question. Structural studies of protein-translocating AAA+ machines proposed a coupled and sequential translocation process, whereby ATP hydrolysis events lead to short threading steps. Yet, direct real-time observation of these events remains elusive.
Here, we employ single-molecule FRET spectroscopy to track substrate translocation through ClpB, a quality control AAA+ machine. We isolate ClpB and its substrate within lipid vesicles and find that translocation events, while dependent on ATP, take milliseconds, much faster than ATP hydrolysis times. Surprisingly, the translocation rate depends weakly on temperature and ATP concentration.
Using three-color FRET experiments, we find that translocation events can occur bidirectionally but are not always complete.
Replacing ATP with the slowly hydrolysable analog ATPγS abolishes both rapid translocation and directionality.
These results indicate a fast, stochastic Brownian-motor-like mechanism, redefining how ATP is coupled with mechanical action in AAA+ machines."

Revolving Doors and Efficient Engines: How Proteins Escape a Molecular Tangle - Chemistry | Weizmann Wonder Wander - News, Features and Discoveries "A new study reveals how energy-efficient cellular machines rapidly untangle misfolded proteins – a finding that may help improve the design of artificial molecular machines"



Fig. 1: Observation of multiple fast events of translocation through the lumen of ClpB facilitated by porous vesicles.


Fig. 4: Translocation of casein in both the forward and backward directions is observed in three-color experiments.


Tuesday, April 28, 2026

Research improves molecular probe of protein binding sites for drug discovery

Good news!

"... The invention works with an existing lab method called photo-crosslinking. Leaving behind a clean, uniform chemical signature, the technology allowed the team to directly compare how different molecules compete for the same binding site on a protein, all in a single experiment. Because most small-molecule drugs act by binding to specific protein targets, finding precisely where these molecules bind is a major benefit for drug discovery.

As proof of concept, the team analyzed the activity of dasatinib and ascinimib, two cancer drugs that target different sites on the same protein, a type of enzyme called a kinase that, when mutated, causes leukemia.
The results coincided with known interactions for each drug and revealed previously unknown interactions. The newer drug, ascinimib, which has a more favorable safety profile and fewer side effects, showed fewer off-target kinase interactions. ...

new technology, called SEE-CITE, is giving the molecule being studied the ability to detach from its payload so that each tagged molecule leaves behind a consistent calling card. This makes possible quantitative measurements and comparisons of how strongly different molecules engage a given binding site. The team also upgraded a widely used software tool to better interpret the complex data this method generates. ..." 

From the abstract:
"For chemical probe and drug discovery campaigns, the pairing of mass spectrometry-based chemoproteomics with photoaffinity labelling has emerged as a favoured approach for target discovery and mode of action assignment. However, photocrosslinked peptide-compound adducts raise analytic challenges for quantitative binding site discovery.
Here, to address these challenges, we establish the Silyl Ether Enables Chemoproteomic Interaction and Target Engagement (SEE-CITE) method. SEE-CITE incorporates a fully functionalized chemically cleavable photocrosslinking handle that enables precise site-of-labelling identification and head-to-head comparisons of relative binding site engagement by chemically diverse compounds.
To ensure high-confidence localization of labelled residues, we extended the MSFragger algorithm of the FragPipe computational platform to report localization scores customized for photoaffinity labelling and SEE-CITE data.
When applied to scout fragments and analogues of select FDA-approved kinase inhibitors, SEE-CITE delineates known drug binding sites and uncovers small-molecule binding sites that affect the protein activity of RTN4 and COX5A."

UCLA research improves molecular probe for drug discovery | UCLA



Fig. 1: Establishing the SEE-CITE interaction site mapping platform using scout SEE-CITE probes.




Fig. 3: SEE-CITE mapping of ABL1 binding sites.


Monday, April 20, 2026

Discovery could lead to new therapies for blood disorders

Good news!

"... investigators have revealed the detailed workings of a cell membrane protein that has essential roles in all animals. The discovery could lead to new therapeutic strategies for blood coagulation disorders, cancers and other conditions in which the protein, called a TMEM16 scramblase, works abnormally.

Scramblases operate within cell membranes, where they alter or “scramble” the normal layered arrangement of lipid molecules – an essential step in many biological processes. The scramblase TMEM16F also works as an ion channel, allowing small, charged molecules such as potassium or chloride ions through the membrane. ...

the researchers at last attained this goal by embedding the protein in liposomes – tiny lipid capsules – which allowed them to image its active and inactive structures at near-atomic-scale resolution. ...

TMEM16F’s rearrangement of cell membrane lipids enables platelet cells to clump together to make blood coagulate, and a mutation affecting the scramblase underlies Scott syndrome, a hemophilia-like bleeding disorder.
The protein is also involved in the formation of the placenta in pregnancy, bone development and immune functions; and it is exploited or suppressed in various cancers and infections. ..."

From the abstract:
"The ubiquitous transmembrane protein 16F (TMEM16F) Ca2+-activated channel and scramblase catalyzes phosphatidylserine externalization to enable blood coagulation, membrane fusion and brain immune surveillance.
Despite its importance, the molecular mechanisms underlying TMEM16F activation remain poorly understood.
Here, we obtained high-resolution cryo-electron microscopy structures of TMEM16F active in liposomes. In high-activity conditions, TMEM16F adopts two conformations, the canonical Ca2+-bound closed state and one where the upward rotation of the cytosolic domain leads to an X-shaped groove that forms a transmembrane pore and locally thins the membrane.
Using mutagenesis, functional assays and molecular dynamics simulations, we show that the X-shaped groove is active and mediates nonselective ion flux and lipid scrambling through distinct pathways; ions move within the protein-delimited pore, whereas lipids skirt the X-shaped groove.
Our findings provide a complete picture of TMEM16F Ca2+-dependent gating and demonstrate that imaging membrane proteins in a native-like environment can allow capturing otherwise inaccessible active states."

Discovery could lead to new therapies for blood disorders | Cornell Chronicle



Fig. 1: Structure of purified TMEM16F reconstituted in liposomes.


Fig. 5: Activation of TMEM16F.


Thursday, March 26, 2026

How huntingtin proteins travel in the brain

Amazing stuff!

"Mutant huntingtin protein, which causes the neurodegenerative disorder Huntington’s disease, travels through the brain using tiny ‘tunneling nanotubes’, research has revealed. Researchers found that a protein called Rhes binds with a protein for cellular acidity regulation, SLC4A7, to build tube-like structures creating a highway to shuttle huntingtin from neuron to neuron. Interrupting this pathway minimised the spread of huntingtin in the brain and offers a potential druggable target."

From the abstract:
"Tunneling nanotubes (TNTs) are membranous structures that mediate intercellular transfer of proteins, including the pathogenic mutant Huntingtin (mHTT) protein in Huntington disease (HD).
We previously identified the ras homolog enriched in the striatum (Rhes) as a key regulator of TNT formation and mHTT transmission; however, the molecular components underlying this process remained unknown.
Here, using unbiased liquid chromatography–tandem mass spectrometry analysis of membrane-associated Rhes complexes, we identify Slc4a7 (solute carrier family 4 member 7), an intracellular pH sensor, as a top membrane-binding partner of Rhes.
Functional studies revealed that small interfering RNA–mediated depletion or pharmacological inhibition of Slc4a7 substantially reduced Rhes-induced TNT formation and suppressed mHTT intercellular transfer.
Mechanistically, Rhes directly interacts with Slc4a7 through both its amino- and carboxyl-terminal domains and modulates intracellular pH to facilitate TNT formation. This interaction does not depend on the transporter activity of Slc4a7. However, inhibition of Rhes farnesylation—a lipid modification that anchors Rhes to the membrane—disrupts its binding to Slc4a7 and abolishes TNT formation.
Slc4a7 knock-out mice showed markedly reduced cell-to-cell transmission of mHTT in the striatum in vivo.
Together, these findings uncover a previously unrecognized Rhes-Slc4a7 signaling axis critical for TNT-mediated mHTT transmission and highlight Slc4a7 as a potential therapeutic target to limit disease spread in HD."

Targeting Tunneling Nanotubes Reduces Spread of Mutant Huntington’s Protein

Membrane-associated Rhes-Slc4a7 complex orchestrates tunneling nanotube formation and mutant Huntingtin spread (open access)


Fig. 1. Membrane-anchored Rhes drives the formation of TNTs between cells.


Tunneling nanotubes connect Rhes expressing striatal neuronal cells



Wednesday, February 04, 2026

Aging slows breakdown of synaptic proteins, raising disease risk

Recommendable!

"In brief
  • A new study reveals mechanisms linking synapse loss to cognitive decline and dementia in aging brains, highlighting critical changes during this process.
  • Researchers found that aging slows the breakdown of synaptic proteins, leading to accumulation that may contribute to diseases like Alzheimer’s.
  • Stanford’s innovative tagging method could enable tracking of neuronal proteins, facilitating the identification of new biomarkers for assessing brain health.
...

Now, researchers ... have discovered clues that may tie synapse loss to another hallmark of brain aging: the declining ability of brain cells to break down and recycle damaged proteins. ...

that synaptic proteins are particularly susceptible to this age-related garbage-disposal problem: In old age, synaptic proteins break down much more slowly, they become more likely to pile up into the tangled clumps of protein characteristic of neurodegenerative disease, and they are more likely to make their way into microglia, immune cells that prune away damaged synapses. ..."

From the abstract:
"Neurodegenerative diseases affect 1 in 12 people globally and remain incurable. Central to their pathogenesis is a loss of neuronal protein maintenance and the accumulation of protein aggregates with ageing.
Here we engineered bioorthogonal tools that enabled us to tag the nascent neuronal proteome and study its turnover with ageing, its propensity to aggregate and its interaction with microglia.
We show that neuronal protein half-life approximately doubles on average between 4-month-old and 24-month-old mice, with the stability of individual proteins differing among brain regions.
Furthermore, we describe the aged neuronal 'aggregome', which encompasses 1,726 proteins, nearly half of which show reduced degradation with age. The aggregome includes well-known proteins linked to diseases and numerous proteins previously not associated with neurodegeneration.
Notably, we demonstrate that neuronal proteins accumulate in aged microglia, with 54% also displaying reduced degradation and/or aggregation with age. Among these proteins, synaptic proteins are highly enriched, which suggests that there is a cascade of events that emerge from impaired synaptic protein turnover and aggregation to the disposal of these proteins, possibly through microglial engulfment of synapses. These findings reveal the substantial loss of neuronal proteome maintenance with ageing, which could be causal for age-related synapse loss and cognitive decline."

Aging slows breakdown of synaptic proteins, raising disease risk | Stanford Report "Recent research unveils new links between the brain’s waste management systems and neurodegeneration. The findings may provide insights for early disease identification."



Images of mouse brain cells, with neurons in red and protein aggregates in green. Those protein aggregates are far more likely to form in older mice (right) compared with younger mice (left), which may contribute to slower breakdown of damaged proteins.


Tuesday, January 06, 2026

Machine learning reveals hidden dimensions of functional similarity in proteins

Recommendable!

Caveat: I did not read the entire, long article.

"Large language models trained on biological sequences, rather than natural language, are transforming biology, from predicting human genetic disease (1, 2) to the design of new-to-nature proteins (3–5). In this issue of PNAS, Cao et al. (6) extend these applications to detect the molecular underpinnings of phenotypic convergence by decoding patterns invisible to traditional sequence analysis approaches ...

Protein Language Models: Decoding Molecular Convergence

Protein language models (PLMs)—deep neural networks trained on millions of protein sequences—have emerged as powerful approaches for capturing the complex relationships between protein sequence, structure, and function (15–18). These models, adapted from natural language processing architectures, like transformers, learn to represent proteins as high-dimensional embeddings, numerical vectors that encode information about structural propensities, functional annotations, mutational effects, and evolutionary constraints.
PLMs are trained through self-supervised learning on large databases of protein sequences without explicit structural or functional labels. By learning to predict hidden amino acids (masked learning) or the next residue in a sequence (autoregressive), these models develop a representation of the “grammar” of proteins—which combinations of amino acids are permissible, which residues tend to co-occur, and which patterns correlate with specific structural and functional properties (3, 19–21). ...

They show that ACEP [Adaptive Convergence by Embedding of Protein] successfully identifies embedding-level convergence across the three test cases, demonstrating that PLMs have learned to recognize functional similarities. ..."

From the significance and abstract:
"Significance
In biology, repeated emergence of the same functional trait in evolution is important as it provides opportunity to decode the relations between genome or protein sequences to specific functions. Such functional convergence has been largely linked to sequence convergence at the level of single sites, because conventional methods cannot measure similarity of high-order features of sequences. This study reveals that the recent protein language models can extract embeddings from protein sequences reflecting high-order features, and develops statistical tests to evaluate the adaptive convergence of such features. The findings emphasize an underrated sequence basis for functional trait convergence in evolution, provide corresponding detection framework, and demonstrate potential power of deep learning in investigating the complex sequence–function mapping in evolutionary biology.

Abstract
Convergent evolution, or convergence, refers to repeated, independent emergences of the same trait in two or more lineages of species during evolution, often indicating functional adaptation to specific environmental factors.
Many computational methods have been proposed to investigate the genetic basis for organismal functional convergence, as an important way to decode the complex sequence–function map of proteins. These methods mostly focus on the convergence of amino acid states at the level of individual sites in functionally related proteins.
However, even without site-level sequence similarity, protein function similarity may also stem from convergence of high-order protein features, which cannot be captured by the conventional methods.
To fill this gap, we first derived numerical embeddings from protein sequences by pretrained protein language models (PLM).
In four previously reported cases, we found that functionally convergent proteins have similar embeddings despite no site-level convergence, indicating that PLM embeddings can reflect convergence of high-order protein features.
We then designed a pipeline to detect Adaptive Convergence by Embedding of Protein (ACEP). ACEP tests were significant on known and additional candidate genes with putative adaptive convergence like echolocation and crassulacean acid metabolism.
Genome-wide application showed that the ACEP framework can effectively enrich such candidates. Relations between convergences of PLM embeddings and specific protein physicochemical features were further examined.
In conclusion, PLM embeddings can indicate adaptive convergence of high-order protein features beyond site identities, demonstrating the power of deep learning tools for investigating the complex mapping between molecular sequences and functions."

Machine learning reveals hidden dimensions of functional similarity in proteins | PNAS



Fig. 1 Detecting molecular convergence using protein language model embeddings.


Saturday, December 06, 2025

Protein-prediction tools based on AI (AlphaFold family) revolutionize science

Good news! Amazing stuff!

"AlphaFold2 — the revolutionary artificial intelligence (AI) tool that predicts highly accurate 3D structures of proteins from sequence data — was unveiled by its creators at Google DeepMind five years ago this month.
An update of the tool, AlphaFold3, was released last year. It can predict how potential therapeutics could interact with proteins. It may take a while for AlphaFold’s biological insights to translate to drug discovery, but the platform has already established itself as top dog in the protein-structure prediction arena.
One analysis identified more than 200,000 studies that used AlphaFold directly or indirectly, encompassing work by nearly 800,000 scientists. ..."

"... The 2021 release of AlphaFold2’s code and a database that has swelled to hundreds of millions of predicted structures mean that scientists can now get a reliable prediction for almost any protein. ...

Some 3.3 million users in more than 190 countries have accessed the AlphaFold database (AFDB), which is hosted by EMBL–EBI and contains more than 240 million structural predictions, encompassing most known proteins. More than one million AFDB users come from low- and middle-income countries, including China and India ..."

Nature Briefing: Translational Research

AlphaFold is five years old — these charts show how it revolutionized science "Since it was unveiled in 2020, Google DeepMind’s game-changing AI tool has helped researchers all over the world to predict the 3D structures of hundreds of millions of proteins."




Very impressive!





Thursday, December 04, 2025

A tiny protein complex controls fat cell size and lipid storage

Good news!

"Scientists have made a major breakthrough in understanding how fat cells grow in size, in response to accommodating larger droplets of fat. The findings unlock a new path in tackling obesity, by reducing the amount of fat our cells can store away. ...

Earlier ... research had identified a protein known as seipin that was critical for healthy lipid storage across organisms, including humans. But how seipin was facilitating this remained unknown, and despite some studies naming another protein – adipogenin – in the process, scientists didn't know how it was involved.

Using cryo-electron microscopy, the researchers found that adipogenin was more than a bystander in the process, reinforcing seipin's structural integrity to enhance its ability to form and deliver lipid droplets to cells. The result is adipocytes accommodating larger lipid droplets – and increasing the size of these fat cells. ..."

From the abstract of the Perspective:
"Obesity is characterized by the accumulation of triacylglycerols in lipid droplets of adipocytes (fat cells) and the expansion of adipose tissue. Adipocytes arise from stem cells through adipogenesis, a process driven by several transcription factors ... Li et al. (3) identify adipogenin as a molecular switch that shifts the emphasis from generating new lipid droplets to expanding existing ones during adipogenesis."

From the editor's summary and abstract:
"Editor’s summary
Fat storage in the body relies on specialized structures called lipid droplets (LDs). Li et al. identified the microprotein adipogenin as a regulator of adipocyte LD size ... Adipogenin interacts with the membrane protein seipin and stabilizes the assembly of seipin dodecamers by bridging adjacent subunits. Functionally, seipin-adipogenin complexes promote the formation of fewer but larger LDs. In mice, adipocyte-specific adipogenin overexpression results in increased fat mass and larger LDs, whereas adipogenin deletion reduces fat accumulation and LD size, particularly in brown adipose tissue. Thus, adipogenin represents a modulator of adipocyte lipid storage that acts through a structural and functional partnership with seipin. ... 

Abstract
INTRODUCTION
Adipogenin (Adig) is an 80–amino acid microprotein that is highly expressed in adipose tissues and steatotic liver. A previous genome-wide association study suggested that human ADIG is associated with blood leptin levels, highlighting its importance in energy metabolism. At the molecular level, Adig’s function is largely unknown: No interacting proteins have been identified. ...

RATIONALE
Microproteins typically exert their functions by binding to larger proteins and regulating their activities. We pulled down Adig from adipocytes and identified its interacting proteins by mass spectrometry. Upon the identification of a seipin-Adig complex, we resolved its structure using cryo–electron microscopy (cryo-EM), enabling us to determine Adig’s effect on seipin configuration at an atomic scale. Because seipin plays a vital role in lipid droplet (LD) formation and growth, we explored the function of the seipin-Adig complex in these processes. Moreover, we generated adipocyte-specific Adig overexpression and deletion mice to investigate Adig’s effect on adipose tissue expansion and lipid metabolism in vivo.

RESULTS
We found that Adig is a highly conserved protein with a single transmembrane (TM) segment that localizes to the endoplasmic reticulum (ER). Notably, Adig and seipin can form a complex and stabilize each other.
Cryo-EM analysis revealed two distinct oligomers: an undecameric seipin-alone complex at ~3.2-Å overall resolution and a dodecameric seipin-Adig complex at ~3.0-Å overall resolution.
In the seipin-Adig complex map, extra densities, corresponding to seipin and Adig TM domains, were observed. Multiple approaches, including high-resolution imaging, gel filtration, and molecular dynamics simulations, revealed that Adig could facilitate the assembly of dodecameric seipin complexes. Seipin complexes with varying Adig contents modulated LD formation and growth. The presence of the seipin-Adig complex altered triacylglycerol (TAG) flux in the ER, leading to the formation of fewer, but larger, LDs.
Additionally, the ER-to-LD trafficking of select lipid-synthesizing enzymes was accelerated in Adig-expressing cells.
In mice, Adig overexpression in adipocytes promoted LD enlargement and adipose tissue expansion, whereas Adig deletion decreased the amount of the seipin complexes in adipocytes and impaired TAG accumulation in brown adipose tissues.

CONCLUSION
In this study, we demonstrate that Adig complexes with seipin, forming a previously unrecognized dodecameric seipin complex. Furthermore, Adig stabilizes and promotes the assembly of this complex, thereby supporting LD growth in cells. In mice, modulating the expression of seipin-Adig complexes in adipose tissues by Adig overexpression or deletion substantially affects LD formation and expansion as well as lipid absorption by adipose tissues. This study reveals Adig as a key cofactor that modulates seipin function and fat storage in adipose tissue. We conclude that the oligomerization and function of seipin complexes can be modulated by Adig expression."

A key protein controls fat cell size and lipid storage

Seipin-adipogenin controls lipid storage in fat cells (Perspective, no public access) "A protein complex promotes the expansion of lipid droplets during the formation of mature adipocytes"

Microprotein plays vital role in fat accumulation (original news release) "Findings from UTSW researchers, colleagues could lead to new treatments to improve metabolic health and reduce risks of obesity, diabetes"


Adipogenin Dictates Adipose Tissue Expansion by Facilitating the Assembly of a Dodecameric Seipin Complex (preprint, open access, but seems to be dated and does not match the journal article)


Seipin-Adig complex promotes the development of lipid droplets.